Valerio TherapeuticsXPAR:ALVIO +37.84%28 Days Payable is 1,283.14 as of Dec. 2025, which is 58% below its 10-year median of 3,079.04. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 702 Biotechnology companies, Valerio Therapeutics ranks better than 89.6% on this metric.
The historical rank and industry rank for Valerio Therapeutics's Days Payable or its related term are showing as below:
XPAR:ALVIO'
s Days Payable Range Over the Past 10 Years
Min: 1622.46 Med: 3079.04 Max: 8574.1
Current: 1668.72
During the past 13 years, Valerio Therapeutics's highest Days Payable was 8574.10. The lowest was 1622.46. And the median was 3079.04.
XPAR:ALVIO's Days Payable is ranked better than 89.6% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs XPAR:ALVIO: 1668.72
Valerio Therapeutics's Days Payable
declined
from Dec. 2024 (2,312.54) to Dec. 2025 (1,283.14).
It may suggest that Valerio Therapeuticsaccelerated paying its suppliers.
Valerio Therapeutics Days Payable Related Terms
Valerio Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVIO vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Valerio Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Valerio Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (XPAR:ALVIO) has a Days Payable of 1,283.14 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valerio Therapeutics and its competitors. This is 58% below median its historical median of 3,079.04. Over the past decade, Valerio Therapeutics' Days Payable has ranged from 1,622.46 to 8,574.10. According to the industry distribution chart, Valerio Therapeutics ranks #73 out of 702 companies in the Biotechnology industry, placing it in the top 10.4%.
Is Valerio Therapeutics' Days Payable too high?
Valerio Therapeutics' current Days Payable of 1,283.14 is 58% below median its 10-year median of 3,079.04. Over the past 10 years, this metric has ranged from a low of 1,622.46 to a high of 8,574.10. The Biotechnology industry median Days Payable is 113.10. Valerio Therapeutics' value of 1,283.14 is 1034.5% above this industry median. Based on the distribution chart, Valerio Therapeutics ranks #73 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #73 out of 702 companies for Days Payable. This places Valerio Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Valerio Therapeutics' value of 1,283.14 is 1034.5% above this benchmark. Historically, Valerio Therapeutics' own Days Payable has ranged from 1,622.46 to 8,574.10 over the past decade. While the company's 10-year median is 3,079.04 vs. the industry median of 113.10, Valerio Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valerio Therapeutics's current Days Payable of 1,283.14 is 1034.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valerio Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valerio Therapeutics's current Days Payable is 1,283.14, which is 58% below median its own 10-year median of 3,079.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current Days Payable is 1,283.14, which is 58% below median its 10-year median of 3,079.04 and 1034.5% above the Biotechnology industry median of 113.10. Valerio Therapeutics' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Days Payable is 1,283.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for XPAR:ALVIO:
Days Payable: 1,283.14 (58% below median its 10-year median of 3,079.04)
GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
Industry Position: 1034.5% above the Biotechnology median (#73 of 702)
No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score
Get the complete analysis for XPAR:ALVIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVIO has been successfully added to your 
